• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

Galen Institute

  • Home
  • About Us
    • Mission and History
    • Grace-Marie Turner bio
    • Who was Galen?
  • Activities
    • Core Activities
    • Commentary and Oped Tutorial
    • Our Book
    • Galen Guides
  • Contact Us
  • Major Papers
  • Broadcast Interviews
  • Health Policy Consensus Group

Response to New York Times Article on Medicare Drug Spending

POSTED BY Galen Institute on February 2, 2006.

Dear Editor:

 

Your Feb. 2 article, "Medicare Drug Spending Expected to Be Well Below Estimates," was a powerful rebuttal to critics who claim Part D's market-based approach is failing. As you note, "the intense competition among private insurers" has resulted in lower prices for both medicines and premiums.

 

The drug benefit certainly stumbled out of the gates, and critics charged it showed a failure of the innovative market-based approach to delivering the benefit. In fact, most of the launch-phase problems can be traced to government computers. In particular, when low-income seniors were switched from Medicaid to Medicare to get their drug coverage, federal and state computer programs weren't compatible and names were dropped. And many seniors didn't get enrollment letters because state address lists were out of date.

 

There's plenty of blame to go around, including understaffing of help lines by private insurers. But the real snafu was on the government side.

 

Sincerely,

 

Grace-Marie Turner

President

Galen Institute

Original story at www.nytimes.com

 

Filed Under: Uncategorized

Response to New York Times Article on Medicare Drug Spending

POSTED BY Galen Institute on February 2, 2006.

Dear Editor:

 

Your Feb. 2 article, "Medicare Drug Spending Expected to Be Well Below Estimates," was a powerful rebuttal to critics who claim Part D's market-based approach is failing. As you note, "the intense competition among private insurers" has resulted in lower prices for both medicines and premiums.

 

The drug benefit certainly stumbled out of the gates, and critics charged it showed a failure of the innovative market-based approach to delivering the benefit. In fact, most of the launch-phase problems can be traced to government computers. In particular, when low-income seniors were switched from Medicaid to Medicare to get their drug coverage, federal and state computer programs weren't compatible and names were dropped. And many seniors didn't get enrollment letters because state address lists were out of date.

 

There's plenty of blame to go around, including understaffing of help lines by private insurers. But the real snafu was on the government side.

 

Sincerely,

 

Grace-Marie Turner

President

Galen Institute

Original story at www.nytimes.com

 

Filed Under: Uncategorized

Primary Sidebar

Our Annual Report

Health Care Choices 20/20:

A Vision for the Future

SEARCH

Categories

  • Brian Blase
  • Consumer-Directed Care
  • Doug Badger
  • Grace-Marie Turner
  • Health Insurance
  • Health Policy Consensus Group
  • Health Savings Accounts
  • Innovation
  • Medicaid
  • Medical Education
  • Medicare
  • Newsletter
  • ObamaCare
  • Prescription Drugs
  • Published
    • Forbes
    • Fox Business
    • Health Affairs
    • LA Times
    • National Review
    • New York Post
    • RealClearHealth
    • Sun Sentinel
    • The Daily Signal
    • The Heritage Foundation
    • The Hill
    • The New York Times
    • The Wall Street Journal
    • The Washington Times
  • Reform Initiatives
  • State Issues
  • Uncategorized

LATEST NEWSLETTER ISSUES

SUBSCRIBE

Social Media

Like Us On Facebook

Twitter: @galeninstitute

 

Copyright Galen Institute at Donors. © 2023; · Log in